Financial Performance - The company reported a revenue of RMB 1.5 billion for the fiscal year 2024, representing a 20% increase compared to the previous year[17]. - The company's operating revenue for 2024 reached ¥1,377,898,264.65, representing a year-on-year increase of 7.15% compared to ¥1,285,988,243.93 in 2023[25]. - The net profit attributable to shareholders of the listed company was -¥18,093,809.99, a significant improvement from -¥70,956,239.35 in the previous year[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥83,215,469.70, an improvement from -¥192,739,350.74 in the previous year[25]. - The company achieved total operating revenue of 1,377.90 million RMB, an increase of 91.91 million RMB, or 7.15% year-on-year[38]. - The net profit attributable to the parent company was -18.09 million RMB, a year-on-year improvement of 52.86 million RMB[38]. - The net cash flow from operating activities was -¥9,681,648.68, a decrease of 106.33% compared to ¥152,987,968.81 in 2023[25]. - The company's total assets decreased by 12.14% to ¥5,048,663,079.32 from ¥5,746,172,538.46 in 2023[25]. - The net assets attributable to shareholders decreased by 2.09% to ¥3,945,243,056.67 from ¥4,029,387,759.53 in 2023[25]. Research and Development - Investment in R&D increased by 30%, focusing on the development of monoclonal antibodies and high-throughput screening technologies[17]. - The R&D expenditure as a percentage of operating revenue was 21.80%, down from 26.33% in the previous year, indicating a decrease of 4.53 percentage points[26]. - The company filed 70 new patent applications during the reporting period, including 55 invention patents, and obtained 56 authorized patents, including 28 invention patents[38]. - The company developed over 320 new products in the life sciences sector, focusing on enhancing performance and cost savings for customers[41]. - The company has developed over 1,900 types of biological reagents, enhancing its product offerings in molecular biology, nucleic acid extraction, high-throughput sequencing, and molecular diagnostics[85]. - The company has developed over 80 new drug research reagents, including products for high-throughput screening and biological activity detection, catering to different stages of drug development[178]. Product Development and Innovation - The introduction of a new point-of-care testing (POCT) product is anticipated to generate an additional RMB 200 million in revenue in 2024[17]. - The new AI-driven enzyme development platform improves screening efficiency by 50% and reduces development cycle by approximately 25%[43]. - The automated nucleic acid extraction solution achieves over 95% extraction efficiency while maintaining cost-effectiveness compared to traditional methods[47]. - The company has developed a series of Alzheimer's disease detection products based on a chemiluminescence platform, with the highest number of registered test kits for core biomarkers in China[67]. - The company has launched a series of magnetic cell sorting kits, including Mouse CD4+ T Cell Isolation Kit, Mouse B Cell Isolation Kit, and Mouse Pan B Cell Isolation Kit, providing efficient solutions for immunology research and drug development[59]. - The company has developed a series of quantum dot fluorescence immunoassay analyzers, including the QD-S600, QD-S900, and QD-S2000, with throughput capabilities of up to 230 tests per hour and 120 tests per hour respectively[191]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[17]. - The company is actively exploring international markets, focusing on the export of research reagents and molecular diagnostic materials, with ongoing business development in North America and Europe[120]. - The company has established subsidiaries in Hong Kong, the USA, Canada, Indonesia, Singapore, Hungary, Germany, the UK, and Australia, enhancing its global supply chain capabilities[122]. - The company has launched multiple nationwide multi-center research projects and academic conferences to promote Alzheimer's disease detection[133]. - The company has expanded its service network to cover 3,200 terminal customers for its in vitro diagnostic products[132]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[6]. - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[6]. - The company has not reported any instances where more than half of the directors could not guarantee the authenticity, accuracy, and completeness of the annual report[9]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company has not violated decision-making procedures for external guarantees[9]. Operational Efficiency - The company implemented a comprehensive production order execution system (MES) that achieved 100% coverage of all production orders, significantly enhancing quality management precision and consistency[91]. - The annual operating costs were significantly reduced, with finished product scrap rates decreasing by 60% year-on-year due to process parameter optimization and inventory management improvements[91]. - The company’s logistics network was expanded to cover 11 provinces, achieving a 71% increase in daily processing capacity at warehouses and a 117% increase in cross-regional delivery capabilities[141]. - The company has implemented a digital platform for production and material planning, enhancing manufacturing efficiency and inventory turnover rates by 28%[141]. - The company has adjusted its organizational structure, resulting in a workforce of 2,867 employees, with 37.43% holding master's degrees or higher[159]. Customer Engagement and Satisfaction - The company achieved a significant improvement in customer satisfaction and loyalty through refined management strategies and tailored service solutions, enhancing its competitive position in the market[88]. - The company has established long-term supply relationships with dozens of clients, significantly increasing sales and leading the domestic market share for GLP-1 raw materials[80]. - The company has implemented a comprehensive training program, conducting over 300 sessions to enhance employee skills and ensure high-quality product delivery[111]. Risk Management - The company emphasizes the importance of risk factors that may adversely affect its operations, as detailed in the management discussion and analysis section[5]. - The company's future plans and development strategies are subject to risks and do not constitute a substantive commitment to investors[8].

证券代码：688105 证券简称：诺唯赞 公告编号：2025-018 南京诺唯赞生物科技股份有限公司 关于2025年中期分红方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）根据中国证监会《上 市公司监管指引第3号—上市公司现金分红（2023年修订）》《上海证券交易所 科创板股票上市规则（2024年4月修订）》《上海证券交易所科创板上市公司自 律监管指引第1号—规范运作（2023年12月修订）》等相关法律法规及《公司章 程》的规定，为进一步加大投资者回报力度，提高投资者回报水平，结合公司实 际情况拟定2025年中期分红方案，具体内容如下： 一、2025年中期分红安排 公司拟于2025年中期（包含半年度、前三季度），在当期盈利、累计未分配 利润为正、公司现金流可以满足正常经营和持续发展需求，并且符合《公司章程》 规定的其他利润分配条件的前提下，进行分红，分红总额不超过相应期间归属于 公司股东的净利润。 为简化分红程序，董事会提请股东大会授权董事会在符合分红条件下处理 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-010 南京诺唯赞生物科技股份有限公司 2024年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配预案内容 （一）利润分配方案的具体内容 经立信会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司2024年度合并报表实现归属于上市公司股东的净利润为人民币-18,093,809.99 元，公司 2024 年末母公司可供分配利润为人民币 1,322,789,735.46 元。公司 2024 年度拟以实施权益分派股权登记日登记的总股本为基数分配利润，具体分配方案 如下： 以实施权益分派股权登记日登记的总股本为基数，拟向全体股东每 10 股派 发现金红利 1.50 元（含税）。截至 2025 年 3 月 31 日，公司总股本为 397,734,544 股，以此计算合计拟派发现金红利 59,660,181.60 元（含税）。2024 年度公司不 送红股，不进行资本公积转增股本。 1 每股分配比例： ...

前十大流通股东累计持有： 30466.95万股，累计占流通股比： 75.76%，较上期变化： 20224.90万股。 | 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 南京诺唯赞投资管理有限公司 | 16190.73 | 40.26 | 新进 | | 国寿成达(上海)健康产业股权投资中心(有限合伙) | 3095.80 | 7.70 | 不变 | | 杨奇 | 2187.29 | 5.44 | 不变 | | 曹林 | 2138.90 | 5.32 | 新进 | | 南京博英维创业投资合伙企业(有限合伙) | 1442.83 | 3.59 | 新进 | | 深圳旦恩先锋投资管理有限公司-深圳旦恩创业投资合伙企 业(有限合伙) | 1385.18 | 3.44 | -17.90 | | 南京唯赞创业投资合伙企业(有限合伙) | 1275.88 | 3.17 | 新进 | | 南京诺泰创业投资合伙企业(有限合伙) | 1184.83 | 2.95 | -54.50 | | 珠海广发信德敖东医药产业股权投资 ...

南京诺唯赞生物科技股份有限公司 章 程 2025 年 2 月 | 第一章 总则 3 | | --- | | 第二章 经营宗旨和范围 4 | | 第三章 股份 4 | | 第一节 股份发行 4 | | 第二节 股份增减和回购 7 | | 第三节 股份转让 8 | | 第四章 股东和股东大会 9 | | 第一节 股东 9 | | 第二节 股东大会的一般规定 11 | | 第三节 股东大会的召集 14 | | 第四节 股东大会的提案与通知 15 | | 第五节 股东大会的召开 17 | | 第六节 股东大会的表决和决议 20 | | 第五章 董事会 24 | | 第一节 董事 24 | | 第二节 独立董事 27 | | 第三节 董事会 32 | | 第六章 总经理及其他高级管理人员 39 | | 第七章 监事会 41 | | 第一节 监事 41 | | 第二节 监事会 42 | | 第八章 财务会计制度、利润分配和审计 43 | | 第一节 财务会计制度 43 | | 第二节 内部审计 47 | | 第三节 会计师事务所的聘任 47 | | 第九章 通知及公告 48 | | 第一节 通知 48 | | 第二节 公 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-007 南京诺唯赞生物科技股份有限公司 关于变更注册资本 、修订《公司章程》 并完成工商变更登记换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于近日完成变更注 册资本、修订《公司章程》的工商登记手续，收到南京市市场监督管理局换发的 《营业执照》，现将相关内容公告如下： 一、关于变更公司注册资本的情况 公司分别于 2024 年 12 月 11 日、2024 年 12 月 30 日召开第二届董事会第十 四次会议、2024 年第一次临时股东大会，授权公司董事会办理注销回购股份、 变更公司注册资本及修订《公司章程》等相关事项，并根据相关法规的要求，就 本次注销回购股份事项履行债权人通知程序（公告编号：2024-066、074、075）。 2025 年 2 月 6 日，公司完成了上述回购股份的注销工作，公司总股本、注 册资本分别变更为 397,734,544 股、397,734,544 元，具体详见公 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-006 南京诺唯赞生物科技股份有限公司 关于自愿披露签订战略合作协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司与华大基因近日于深圳市签署了《战略合作协议》，具体情况如下： 一、协议签订的基本情况 （一）协议对方基本情况 | 企业名称 | 深圳华大基因股份有限公司（300676.SZ） | | | | | --- | --- | --- | --- | --- | | 企业性质 | 其他股份有限公司（上市） | | | | | 法定代表人 | 赵立见 | | | | | 注册资本 | 41,582.1575 万元 | | | | | 成立日期 | 2010 月 日 | 年 | 7 | 9 | | 注册地址 | 深圳市盐田区洪安三街 21 号华大综合园 7 栋 7 层-14 层 | | | | | 经营范围 | 贸易经纪与代理。住房租赁；非居住房地产租赁。（除依法须经批准 | | | | | | 的项目外，凭营业执照依法自主开展经营 ...

Financial Performance - The company achieved total operating revenue of CNY 1,370,962,630.03, representing a year-on-year increase of 6.61%[3] - The net profit attributable to the parent company was CNY -17,001,790.83, a reduction in loss of CNY 5,395,440 compared to the previous year[4] - The total assets at the end of the reporting period were CNY 5,051,433,120.96, a decrease of 12.09% from the beginning of the period[4] - The equity attributable to the parent company was CNY 3,946,870,040.93, down 2.05% from the beginning of the period[3] - The company reported a basic earnings per share of CNY -0.04, an improvement from CNY -0.18 in the previous year[3] Business Strategy - The company focused on market demand and development opportunities, leading to rapid growth in new product lines and international business[4] - The company emphasized internal control measures to manage costs and reduce risks[4] Asset Management - The company effectively reduced asset impairment losses, which significantly decreased year-on-year[4] Government Subsidies - The company experienced a substantial reduction in government subsidy-related income during the reporting period[5] Financial Reporting - The financial data presented is preliminary and subject to change upon final audit in the annual report[6]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-004 南京诺唯赞生物科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/6，由公司董事长兼总经理、实际控制人 曹林先生提议 | | --- | --- | | 回购方案实施期限 | 待公司董事会审议通过后 12 个月 | | 预计回购金额 | 8,000 万元~16,000 万元 | | 回购价格上限 | 29.87 元/股 | | 回购用途 | √减少注册资本 □为维护公司价值及股东权益 | | 实际回购股数 | 4,399,299 股 | | 实际回购股数占总股本比例 | 1.09% | | 实际回购金额 | 10,600.41 万元 | | 实际回购价格区间 | 17.65 元/股~28.65 元/股 | 一、回购审批情况和回购方案内容 南京诺唯赞生物科技股份有限公司(以下简称"公司")于 2024 年 2 月 5 日召 开第二届董事会第八次会议，审 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 27.98 CNY [3][6]. Core Views - The company is experiencing rapid growth in overseas business and is optimistic about the volume of new products being launched [2]. - Revenue and profit forecasts have been adjusted downwards due to industry demand fluctuations, reduced income from COVID-19 products, and increased R&D investments [3]. - The company is expected to achieve earnings per share of -0.03 CNY in 2024, 0.27 CNY in 2025, and 0.45 CNY in 2026 [3]. Financial Performance Summary - The company's revenue for 2022 was 3,569 million CNY, with a projected decline to 1,286 million CNY in 2023, followed by a recovery to 1,467 million CNY in 2024, and further growth to 1,845 million CNY in 2025 and 2,287 million CNY in 2026 [5]. - The gross profit margin is expected to improve from 71.0% in 2023 to 77.3% by 2026 [5]. - The net profit attributable to the parent company is projected to recover from a loss of 71 million CNY in 2023 to a profit of 179 million CNY in 2026 [5]. Business Segment Insights - The life sciences segment is seeing stable growth with continuous upgrades and new product launches [7]. - The in vitro diagnostics segment has expanded its reach, covering over 2,800 hospitals with rapid growth in respiratory pathogen detection products [7]. - The biopharmaceutical segment has achieved significant production scale, becoming a major supplier of enzyme raw materials in China [7]. R&D and Cost Management - The company has maintained a strong commitment to R&D, with R&D expenses accounting for 21.8% of revenue in the first three quarters of 2024 [7]. - Effective cost control measures have led to a reduction in management and sales expense ratios [7].